News
January 2023: VAST platform published in a comprehensive paper in Cell Reports.
April 2022: CSO of Hepione, Dr. Joey Verdi, is an invited speaker at the 3rd RNA Editing Summit to present nanoVAST.
June 21, 2021: Founder and CSO Dr. Nina Papavasiliou's laboratory receives DKFZ Innovation Award for her translational efforts with the VAST platform.
February 17, 2021: Hepione was selected to the final round of the XSEED Award, designed to support early-stage life science startups, sponsored by Deerfield Management Company, a New York City-based healthcare investment firm.
November 20, 2020: Founder and CSO Dr. Nina Papavasiliou presents the VAST technology at the 2020 BioRN Annual Conference in Heidelberg. Image link to her recorded presentation
November 1, 2020: Dr. Verdi opens Hepione's incubator space at BioLabs@NYULangone in Manhattan.
September 23, 2020: NIH SBIR grant awarded to Hepione Therapeutics for fentanyl overdose prevention.
Hepione Therapeutics founded to commercialize applications of the VAST technology.